[{"id":"326bdba4-8819-48bd-b77b-d9ba7fb9feb7","acronym":"","url":"https://clinicaltrials.gov/study/NCT05100641","created_at":"2021-10-29T13:53:14.205Z","updated_at":"2024-07-02T16:35:50.965Z","phase":"Phase 3","brief_title":"AV-GBM-1 vs Control as Adjunctive Therapy Following Surgery and RT/TMZ in Newly Diagnosed GBM","source_id_and_acronym":"NCT05100641","lead_sponsor":"Aivita Biomedical, Inc.","biomarkers":" MGMT","pipe":"","alterations":" ","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • AV-GBM-1"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 672","initiation":"Initiation: 01/01/2024","start_date":" 01/01/2024","primary_txt":" Primary completion: 03/01/2028","primary_completion_date":" 03/01/2028","study_txt":" Completion: 03/01/2029","study_completion_date":" 03/01/2029","last_update_posted":"2023-04-10"}]